top border
top border
Featured Programs
Agent That Starves Tumor Cells May Improve Survival in Metastatic RCC
A novel glutaminase inhibitor CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx) by cutting off the energy supply to tumor cells in patients with metastatic renal cell carcinoma.
View Now
Treating Advanced Renal Cell Carcinoma
In this program moderated by Robert Figlin, MD, a panel of experts discusses modern day treatment of advanced kidney cancer. The discussants, Sandy Srinivas, MD; Nizar Tannir, MD, FACP; and Martin Voss, MD, focus on how to choose the right course of treatment for an individual patient.
View Now
Featured Video
Dr. Esteva on the Future of Biosimilars in Breast Cancer
Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now
Gina Columbus

Gina Columbus highlights the latest news in oncology in this week's OncLive News Network.

Publication Bottom Border
Border Publication
x